Open Orphan’s hVIVO awarded CAP accreditation

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that its clinical laboratories in Queen Mary’s Bioenterprise Centre and Plumbers Row (hLab) have been awarded accreditation by the College of American Pathologists. The Company sought the accreditation as part of its ongoing commitment to maintaining best in class quality systems.

The CAP is the world’s largest organisation of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programmes. The accreditation “supports laboratories performing testing on specimens from human, using methodologies and clinical application within the expertise of the program”. This further expands on the Company’s Good Clinical Practice for Laboratories (GCLP) accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA) and provides additional quality assurances of its laboratory services for its clients, especially within the United States, thus ensuring the accuracy of test results and conforming to the requirements from the US Food and Drug Administration (FDA).

hLab is a highly specialised virology and immunology laboratory, offering a suite of services to support both pre-clinical and clinical respiratory drug and vaccine discovery and development. This includes assay development, transfer and optimisation across immunology, molecular and cell-based assays, including extensive options in sample matrix and stability testing and analysis. hLab is well equipped with Biosafety Level 2 and 3 facilities to provide high quality data outputs to enable clients to achieve early proof of concept, or to make a breakthrough discovery in the pathology and possible treatment of diseases with unmet medical needs. hLAB now provides services beyond supporting the Company’s in-house human challenge trials, offering lab services as a standalone service to support vaccine and drug development from pre-clinical studies through Phases I – III clinical trials.

Brandon Londt, Development Operations Director, hLab Development at hVIVO, said: “We are proud to have received the CAP accreditation, which is recognition of the quality of our laboratory and further demonstrates our commitment to maintaining the highest standards of excellence and ensuring that our work practices meet the rigorous CAP assessment standards. This accreditation will provide current and future clients a further degree of confidence in the quality of work performed in our laboratory and assurances of the results we produce.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan three upcoming scientific presentations

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (LON:HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced

Open Orphan Plc

Open Orphan reiterates £50m profit guidance

Dublin and London-listed pharmaceutical company Open Orphan announced on Thursday that it will rename itself Hvivo from next month. The rare and orphan drug consulting services platform also reported results for the first half of the year, revealing

Open Orphan Plc

Open Orphan rebrands to Hvivo

Open Orphan is changing its name as CEO Yamin Khan said the company achieved its ‘key goal’ of double-digit earnings for the first time. Dublin-based pharma services company Open Orphan announced today (8 September) that it is changing

Open Orphan Plc

hVIVO says 3rd virus challenge contract is sign of growing demand

Open Orphan subsidiary hVIVO has been hired to make H1N1 influenza virus for a Phase IIa study of a developmental antiviral drug. The UK-based contract research organization (CRO) announced the £10.4 million ($12.1 million) contract this month, sharing

Open Orphan Plc

Open Orphan to change name to hVIVO plc

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its intention to change its name to hVIVO plc, with

Open Orphan Plc

Open Orphan continued its profitable momentum into 2022

Open Orphan plc (LON:ORPH), (to be renamed hVIVO plc (LON:HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical

Open Orphan Plc

Open Orphan inks £10.4M deal to produce new H1N1 challenge virus

Open Orphan subsidiary hVIVO has inked a 10.4 million pound sterling ($12.3 million) deal with a large, unnamed pharmaceutical company to produce a novel batch of H1N1 influenza challenge virus. In a challenge trial, healthy patients are deliberately infected with

Open Orphan Plc

Clinical trial management

Added value for working with Venn Medical Writing group » End-to-end support: Venn clinical trial management group has the expertise to set-up, coordinate and deliver clinical trials including vendor selection, investigational product logistics, data management, safety analyses, reporting,

Open Orphan Plc

Open Orphan to release its interim results on 8 September 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its interim results for the six

Open Orphan Plc

Venn Life Sciences: Medical writing

Team experience Small dedicated team of Senior Medical Writers and Clinical Trial Assistant with total team experience in clinical and regulatory writing of more than 75 years In addition, Venn is working with a flexible shell to increase

Open Orphan Plc

RSV Human Challenge Study
as a tool for a break-through designation

IntroductionAn international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified vaccinia virus Ankara RSV vaccine candidate. The company

Open Orphan Plc

Open Orphan to commence influenza human challenge study

Candidate exhibits a novel mechanism of action and differs considerably from previously approved drugs Open Orphan – a specialists in testing infectious and respiratory disease products using human challenge clinical trials – has announced that its subsidiary, hVIVO,

Open Orphan Plc

Cocrystal Pharma partners with hVIVO

A growing specialist contract organization, hVIVO—a subsidiary of Open Orphan plc—has been tapped by Cocrystal Pharma to conduct a phase 2a clinical trial of its novel broad-spectrum, orally administered antiviral candidate, CC-42344. Housed in hVIVO’s state-of-the-art facility in

Open Orphan Plc

From bench to clinic: Hurdles in gene therapy development

Gene therapy offers significant potential to treat diseases with high unmet medical need. However, the unique nature of these therapies poses challenges in product development, namely: safety concerns, efficacy issues, or obstacles related to Chemistry, Manufacturing and Controls (CMC). CMC

Open Orphan Plc

What is FluCamp?

FluCamp is all about improving the health of the population, through increasing understanding around common viral illnesses. Ultimately, the more that we understand about how viruses affect the human immune system, the more quickly we can find and

Open Orphan Plc

Open Orphan’s hVIVO signs £6.2m human challenge study contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan plc, has signed a

No more posts to show